Swimming in PD patients with STN-DBS: A pilot exploratory study
Objective: Patients with PD frequently complain of losing abilitiy to swim. Our aim was to test the swimming abilities of our patients with bilateral STN-DBS…Does the Parkinson’s Kinetigraph change clinical practice?
Objective: To assess whether information obtained from Parkinson’s Kinetigraph (PKG) influences clinical decision-making. Background: PKG is a relatively new technology: the device is worn continuously…Motivational effects on action selection and memory
Objective: Eye movements provide important insights into the pathophysiology of neurological disorders. Here two paradigms were devised to quantify effects of motivation on motor control…Dissociative effects of thyrotropin releasing hormone on classical cerebellar ataxic signs and cerebellar adaptation in patients with spinocerebellar degeneration
Objective: To reveal effects of TRH [Thyrotropin releasing hormone (protirelin tartrate)] on the prism adaptation task in patients with spinocerebellar degeneration (SCD). Background: The cerebellum…Pilot economic evaluation of Personal KinetiGraph (PKG) for management of Parkinson’s disease in Australia
Objective: To determine the potential cost savings and quality of life gains with the Personal KinetiGraph (PKG) in the management of patients with Parkinson’s disease…Influence of dopamine deficiency on interhemispheric crosstalk in Parkinson’s disease
Objective: To identify the significance of dopaminergic depletion in Parkinson’s disease (PD) on interhemispheric crosstalk using a complex bimanual tapping task. Background: Dopamine deficiency in…A randomized, double-blind, placebo-controlled Phase II Efficacy and Safety Study of the PDE10A inhibitor PF-02545920 in Huntington Disease (AMARYLLIS)
Objective: To assess efficacy on motor function, safety and tolerability of the phosphodiesterase-10A inhibitor PF-02545920 in Huntington disease (HD). Conclusion: PF-02545920 was generally safe and…Costs and outcomes for Parkinson’s disease patients who have their management adjusted by Personal KinetiGraph (PKG)
Objective: To quantify the potential cost savings and quality adjusted life years (QALYs) gained for people with Parkinson’s disease in Australia whose oral therapy was…Naturalistic-based UPDRS-III Minimal Clinically Important Difference (MCID) in early PD
Objective: To find the MCID of the UPDRS-III subscale in early PD subjects, when started on a new dopaminergic drug. Background: The concept of Minimally…Speech in Huntington’s Disease
Objective: To review existing literature on speech function in Huntington’s disease (HD) across the disease spectrum. Background: Impairment in speech production affects the majority of…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 40
- Next Page »